Page contents Key factsDecisionTopicsKey facts Active Substance Momelotinib Therapeutic area Oncology Decision number P/0249/2019 PIP number EMEA-001656-PIP02-19 Pharmaceutical form(s) Film-coated tablet Condition(s) / indication(s) Treatment of myelofibrosis Route(s) of administration Oral use Contact for public enquiries GlaxoSmithKline Trading Services LimitedTel. +1 438-899-8201E-mail: eu.paediatric-plans@gsk.com Decision type W: decision granting a waiver in all age groups for all conditions or indications Decision date 17/06/2019DecisionP/0249/2019: EMA decision of 17 June 2019 on the granting of a product specific waiver for momelotinib (EMEA-001656-PIP02-19)AdoptedReference Number: EMA/364985/2019 English (EN) (127.84 KB - PDF)First published: 08/11/2019ViewTopicsPaediatricsShare this page